Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma (NimoBenSeq)
Postoperative Radiotherapy And Nimotuzumab With or Without Benmelstobart Adjuvant Therapy in Patients With Head and Neck Squamous Cell Carcinoma Having Intermediate-Risk Pathological Factors: A Multicenter Prospective Randomized Controlled Study
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Listed as NCT07535567, this observational or N/A phase trial focuses on Head and Neck Squamous Cell Carcinoma and remains actively recruiting participants. Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
May 4, 2026 — Present [daily]
Not Yet Recruiting
-
Apr 18, 2026 — May 4, 2026 [daily]
Not Yet Recruiting
First recorded
Eligibility Summary
A multicenter, randomized, controlled, open-label, Phase II/III clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative head and neck squamouscell cancer patients with intermediate-risk pathological factor. The primary endpoint is the 3-year disease-freesurvival (DFS). A total of 193 patients will be enrolled in both the experimental and control groups, resulting in a total planned enrollment of 386 patients.
Contact Information
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.